PTC Therapeutics, Inc. Stock News

PTC Therapeutics, Inc. ( PTCT ) UBS Global Healthcare Conference 2025 November 11, 2025 3:30 PM EST Company Participants Matthew Klein - CEO & Director Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division All right. Good day, everybody.

PTC Therapeutics, Inc. ( PTCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Ellen Cavaleri Matthew Klein - CEO & Director Eric Pauwels - Chief Business Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Tazeen Ahmad - BofA Securities, Research Division Brian Abrahams - RBC Capital ...

– Initiated US and EU launch of Sephience™ (sepiapterin) –  – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 – – Robust Q3 performance with total revenue of $211M – – Full-year 2025 revenue guidance narrowed to $750 - $800M – WARREN, N.J. , Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corpor...

WARREN, N.J. , Oct. 31, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: UBS Global Healthcare Conference 2025 Tuesday, Nov. 11 at 3:30 p.m.

WARREN, N.J. , Oct. 27, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 23, 2025, the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 1,990 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees.

WARREN, N.J. , Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2025 financial results and provide an update on the company's business and outlook on Tuesday, November 4, at 4:30 p.m.

WARREN, N.J. , Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan...